Skip to Content

Peter F. Thall

Present Title & Affiliation

Primary Appointment

Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Peter Thall received his PhD in statistics and probability from The Florida State University Department of Statistics in 1975. He has been a Science Faculty member at M.D. Anderson Cancer Center since 1990, where he holds the Anise J. Sorrell Professorship. Dr. Thall has pioneered application of Bayesian methods in medical research, and designed hundreds of clinical trials. He has published over 190 papers and book chapters in the statistical and medical literature, and presented 27 short courses and over 180 invited talks. He has served as an Associate Editor for the journals Statistics in Medicine, Journal of the National Cancer Institute, and Biometrics, and was the American Statistical Association (ASA) Section on Bayesian Statistical Science Program Chair for the 2013 Joint Statistical Meetings. In 2014, he was made a Fellow of the Society for Clinical Trials, and received the Don Owen award from the San Antonio chapter of the ASA. He currently serves as an Associate Editor for Clinical Trials and Statistics in Biosciences, an ASA Media Expert, a member of the International Biometric Society ENAR Regional Advisory Board, and is Principal Investigator of the NIH/NCI RO1 grant “Statistical Methods for Complex Cancer Trials.”

Click to view personal webpage

Research Interests

Clinical trial design

Adaptive decision making in clinical trials

Bayesian statistics

Dynamic treatment regimes

Geometric methods for constructing decision criteria

Computer-intensive methods in statistics

Education & Training

Degree-Granting Education

1975 Florida State University, Tallahassee, FL, PHD, Statistics & Probability
1973 Florida State University, Tallahassee, FL, MS, Statistics
1971 Michigan State University, East Lansing, MI, BS, Mathematics

Selected Publications

Peer-Reviewed Original Research Articles

1. Lee J, Thall PF, Ji Y, Muller P. Bayesian dose-finding in two treatment cycles based on the joint utility of efficacy and toxicity. JASA. In Press.
2. Thall. Discussion of Analysis of forensic DNA mixtures with artefacts by Cowell, Graversen, Lauritzen and Mortera. J Royal Statistical Society, Series C. In Press.
3. Thall PF, Nguyen HW, Zohar S, Maton P. Optimizing sedative dose in preterm infants undergoing treatment for respiratory distress syndrome. JASA. In Press. PMCID: PMCPMC Journal to Process.
4. Jin I-H, Liu S, Thall PF, Yuan Y. Using data augmentation to facilitate conduct of phase I/II clinical trials with delayed outcomes. JASA. In Press. PMCID: PMCPMC Journal In Process.
5. Wang L, Shen J, Thall PF. A Modified Adaptive Lasso for Identifying Interactions in the Cox Model with the Heredity Constraint. Stat Probab Lett 93:126-133, 10/1/2014. PMCID: PMC4111275.
6. Thall PF, Nguyen HQ, Braun TM, Qazilbash MH. Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes. Biometrics 69(3):673-682, 9/2013. e-Pub 8/19/2013. PMCID: PMC3963428.
7. Wahed AS, Thall PF. Evaluating joint effects of induction-salvage treatment regimes on overall survival in acute leukemia. J R Stat Soc Ser C Appl Stat 62(1):67-83, 1/2013. PMCID: PMC3762505.
8. Wang L, Rotnitzky A, Lin X, Millikan RE, Thall PF. Evaluation of viable dynamic treatment regimes in a sequentially randomized trial of advanced prostate cancer. J Am Stat Assoc 107(498):493-508, (with discussion, pages 509-517), 6/2012. PMCID: PMC3433243.
9. Thall PF, Nguyen HQ, Wang X, Wolff JE. A hybrid geometric phase II/III clinical trial design based on treatment failure time and toxicity. J Stat Plan Inference 142(4):944-955, 4/1/2012. PMCID: PMC3249838.
10. Thall PF, Nguyen HQ. Adaptive randomization to improve utility-based dose-finding with bivariate ordinal outcomes. J Biopharm Stat 22(4):785-801, 2012. PMCID: PMC3385658.
11. Thall PF, Szabo A, Nguyen HQ, Amlie-Lefond CM, Zaidat OO. Optimizing the concentration and bolus of a drug delivered by continuous infusion. Biometrics 67(4):1638-46, 12/2011. e-Pub 3/14/2011. PMCID: PMC3137757.
12. Morita S, Thall PF, Bekele BN, Mathew P. A Bayesian hierarchical mixture model for platelet derived growth factor receptor phosphorylation to improve estimation of progression-free survival in prostate cancer. J R Stat Soc Ser C Appl Stat 59(1):19-34, 9/3/2009. PMCID: PMC2853262.
13. Thall PF, Nguyen HQ, Estey EH. Patient-specific dose finding based on bivariate outcomes and covariates. Biometrics 64(4):1126-36, 12/2008. e-Pub 3/19/2008. PMID: 18355387.
14. Wathen JK, Thall PF, Cook JD, Estey EH. Accounting for patient heterogeneity in phase II clinical trials. Stat Med 27(15):2802-15, 7/10/2008. e-Pub 10/2007. PMID: 17948869.
15. Morita S, Thall PF, Müller P. Determining the effective sample size of a parametric prior. Biometrics 64(2):595-602, 6/2008. e-Pub 8/30/2007. PMCID: PMC3081791.
16. Thall PF, Wooten LH, Logothetis CJ, Millikan RE, Tannir NM. Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med 26(26):4687-4702, 2007. PMID: 17427204.
17. Braun TM, Thall PF, Nguyen H, de Lima M. Simultaneously optimizing dose and schedule of a new cytotoxic agent. Clin Trials 4(2):113-124, 2007. PMID: 17456511.
18. Thall PF, Wooten LH, Shpall EJ. A geometric approach to comparing treatments for rapidly fatal diseases. Biometrics 62(1):193-201, 3/2006. PMID: 16542246.
19. Thall PF, Wathen JK. Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments. Stat Med 24(13):1947-1964, 2005. PMID: 15806621.
20. Thall PF, Sung H-G, Estey EH. Selecting therapeutic strategies based on efficacy and death in multi-course clinical trials. J American Statistical Assoc 97:29-39, 9/2002.
21. Thall PF, Simon RM, Estey EH. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med 14(4):357-379, 1995. PMID: 7746977.

Invited Articles

1. Thall PF. Bayesian adaptive dose-finding based on efficacy and toxicity. J. Statistical Research 14:187-202, 2012.
2. Thall PF. Bayesian models and decision algorithms for complex early phase clinical trials. Stat Sci 25(2):227-44, 5/2010. PMCID: PMC3035990.
3. Thall PF. A review of phase 2-3 clinical trial designs. Lifetime Data Anal 14(1):37-53, 3/2008. e-Pub 9/2/2007. PMID: 17763973.
4. Thall PF. Some geometric methods for constructing decision criteria based on two-dimensional parameters. J Stat Plan Inference 138(2):516-527, 2008. PMCID: PMC2906756.
5. Thall PF, Wathen JK. Practical Bayesian adaptive randomisation in clinical trials. Eur J Cancer 43(5):859-66, 3/2007. e-Pub 2/16/2007. PMCID: PMC2030491.

Grant & Contract Support

Title: Cancer Center Support Grant - Biostatistics Shared Resource (PPSR-21)
Funding Source: NIH/NCI
Role: Statistician
Principal Investigator: Ronald DePinho
Duration: 7/1/2013 - 6/30/2018
Title: Statistical Methods for Complex Cancer Trials
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 7/1/2013 - 4/30/2018
Title: Immunologic Checkpoint Blockade in Cancer Therapy
Funding Source: American Association for Cancer Research (AACR)
Role: Co-Investigator
Principal Investigator: James Allison
Duration: 3/1/2013 - 2/29/2016
Title: Transduction of T cells to improve migration to tumor
Funding Source: NIH/NCI
Role: Statistician
Principal Investigator: Patrick Hwu
Duration: 8/1/2011 - 7/31/2015
Title: Clinical Core MIRA - Cellular Therapy for Cancer
Funding Source: CPRIT (Subcontract from Baylor College of Medicine
Role: Co-Investigator
Principal Investigator: Helen Heslop
Duration: 7/1/2011 - 6/30/2014
Title: Therapy of CML - Biostatistics Core (PC-B)
Funding Source: NIH/NCI
Role: Core Director
Principal Investigator: Richard Champlin
Duration: 9/17/2010 - 6/30/2015
Title: Hematopoietic Progenitor Cells - Cord Blood
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Elizabeth Shpall
Duration: 4/6/2010 - 1/31/2015
Title: MD Anderson Cancer Center Prostate SPORE (PC-B)
Funding Source: NIH/NCI
Role: Investigator
Principal Investigator: Christopher J. Logothetis
Duration: 9/2/2009 - 8/31/2014
Title: Statistical Methods for Complex Cancer Trials
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 5/7/2009 - 6/30/2013
Title: A Novel Autotransplant Protocol for CML
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Marcos De Lima
Duration: 6/8/2004 - 5/31/2007
Title: Rebuilding Immunity for Survival - Biostatistics Core (PC-D)
Funding Source: NIH/NCI
Role: Biostatistics Core Leader
Principal Investigator: Lee Nadler
Duration: 9/30/2003 - 11/30/2009
Title: Therapy of CML (PP-2)
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Richard Champlin
Duration: 2/12/1997 - 2/28/2009

Last updated: 7/7/2014